The Femtosecond Laser in Residency Training (FLIRT) Pilot Study

Sponsor
University of Southern California (Other)
Overall Status
Withdrawn
CT.gov ID
NCT03115216
Collaborator
Alcon Research (Industry)
0
2
12

Study Details

Study Description

Brief Summary

This pilot study aims to primarily assess the rate of complication of anterior vitrectomy for patients undergoing femtosecond laser-assisted (FLA) cataract extraction and intraocular lens placement (CEIOL) compared to manual CEIOL, when performed by resident physicians under direct attending supervision. In this pilot study, the investigators aim to assess what the incidence of anterior vitrectomy is for each group, in order to better understand the sample size needed to assess whether there is a difference between these two groups. Secondarily, it will gather preliminary data on safety and refractive outcomes for patients undergoing these interventions.

Condition or Disease Intervention/Treatment Phase
  • Procedure: FLA-CEIOL
  • Procedure: CEIOL
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
0 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
The Femtosecond Laser in Residency Training (FLIRT) Pilot Study: Femtosecond Laser-Assisted Versus Manual Cataract Extraction and Intraocular Lens Implantation
Anticipated Study Start Date :
Jul 1, 2017
Anticipated Primary Completion Date :
Jul 1, 2018
Anticipated Study Completion Date :
Jul 1, 2018

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: FLA-CEIOL

Femtosecond laser assisted cataract extraction and intraocular lens placement

Procedure: FLA-CEIOL
Femtosecond laser-assisted cataract extraction and intraocular lens placement

Active Comparator: CEIOL

Clear corneal incision with manual cataract extraction and intraocular lens placement

Procedure: CEIOL
Manual cataract extraction and intraocular lens placement

Outcome Measures

Primary Outcome Measures

  1. Incidence of anterior vitrectomy [6 months]

    Of all cases in each group, what percent results in any complication that needed conversion to anterior vitrectomy

Secondary Outcome Measures

  1. Incidence of dropped nucleus or intraocular lens (IOL) [6 months]

    Complication when the nucleus or implanted intraocular lens falls posteriorly

  2. Incidence of posterior capsular tear [6 months]

    Complication where the posterior capsule is torn or ruptured

  3. Incidence of anterior capsular tears or tags [6 months]

    Complication where the anterior capsule is torn or ruptured

  4. Incidence of zonal injury [6 months]

    Complication where the cataractous nucleus or implanted IOL falls posteriorly.

  5. Incidence of corneal injury [6 months]

    Complication when the cornea is injured during surgery

  6. New onset macular edema [6 months]

    Presence of macular edema, by clinical evaluation or optical coherence tomography (OCT), which was not present before surgery

  7. New onset ocular hypertension or glaucoma [6 months]

    Ocular hypertension or glaucoma, which was not present before surgery

  8. Postoperative outcomes such as uncorrected and best corrected distance visual acuity [6 months]

    Measured by manifest refraction

  9. Contrast sensitivity [6 months]

    Measured by Pelli-Robson Contrast Sensitivity Chart and the Contrast Sensitivity Testing (CSV-1000E)

  10. Spherical equivalent [6 months]

    Calculated from the best corrected visual acuity

  11. Corneal edema [6 months]

    Graded by the surgeon on a scale of 0 to 3 (none, mild, moderate, severe)

  12. Central corneal thickness [6 months]

    Measured by pachymetry

  13. Intraocular lens centration [6 months]

    Subjectively graded by the surgeon on a scale of 0 to 4 (poor, average, fair, excellent centration).

  14. Educational gains of the resident surgeon [6 months]

    Done through surveys distributed to resident physicians throughout the course of the study

Eligibility Criteria

Criteria

Ages Eligible for Study:
40 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients of the Los Angeles County + University of Southern California Medical Center (LAC+USC) who are 40 years or older with visually significant cataracts asking for surgical intervention.

  • Cataract must be visually and clinically significant on examination as determined by the resident surgeon and the attending physician.

Exclusion Criteria:
  • Age less than 40

  • Visual acuity 20/30 or better with refraction in the study eye

  • Any previous ocular surgery

  • Patient request for monovision or for correction at near at the expense of distance

  • Patient and physician decision to use an IOL implant other than monofocal IOL

  • Corneal pathology (e.g. Fuch's dystrophy, corneal opacity or scar, corneal ectasia)

  • Posterior or anterior capsular plaque

  • Posterior polar cataract

  • White cataract

  • Subluxated lens, weak zonules, or phacodonesis

  • Pseudoexfoliation syndrome

  • Failure of preoperative pupillary dilatation (< 6 mm dilation)

  • History of uveitis

  • History of retinal detachment

  • Untreated or active proliferative diabetic retinopathy

  • Untreated or active diabetic macular edema

  • Ocular diseases that may affect visual acuity or the operation (including and not limited to macular degeneration, retinitis pigmentosa, macular hole, advanced or end-stage glaucoma)

  • Neurological or systemic diseases that may affect visual acuity or the safety of the operation

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • University of Southern California
  • Alcon Research

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University of Southern California
ClinicalTrials.gov Identifier:
NCT03115216
Other Study ID Numbers:
  • FLIRT
First Posted:
Apr 14, 2017
Last Update Posted:
Sep 24, 2019
Last Verified:
Apr 1, 2017
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 24, 2019